UnitedHealth Group (UNH) Q2 2026: Revenue Growth with Strong Earnings — Positive Outlook

UnitedHealth Group (NYSE: UNH) reported its second quarter 2026 results, showcasing a revenue increase and significant earnings growth compared to the prior year. The company achieved consolidated revenues of $112.0 billion, reflecting an increase of $0.4 billion or +0.4% from $111.6 billion in Q2 2025. Earnings from operations surged to $8.0 billion, up $2.8 billion or +53.8% from $5.2 billion in the same quarter last year.

This quarter's performance is a positive development for shareholders, as the substantial increase in earnings demonstrates effective cost management and operational efficiency. The rise in revenue, albeit modest, indicates resilience in a competitive healthcare market.

Key Financial Metrics:

• Revenues: $112.0 billion (Q2 2025: $111.6 billion)
• Earnings from Operations: $8.0 billion (Q2 2025: $5.2 billion)
• Net Margin: 4.9% (Q2 2025: 3.1%)
• Earnings Per Share (EPS): $6.04 (Q2 2025: $3.74)
• Adjusted EPS: $6.38 (Q2 2025: $4.08)

Operational Highlights:

• Medical Care Ratio: 86.7% (Q2 2025: 89.4%), indicating improved cost management.
• Operating Cost Ratio: 12.7% (Q2 2025: 12.3%), reflecting targeted investments in technology and operations.
• Cash Flows from Operations: $11.1 billion, or 1.9x net income.

UnitedHealth Group also updated its full-year 2026 earnings outlook, raising the guidance for diluted adjusted net earnings per share to a range of $19.50 to $20.00, up from previous estimates. This upward revision is a strong indicator of the company's confidence in its operational strategies and market position.

Shareholder Returns:

The company has been active in returning capital to shareholders, having repurchased $4.0 billion of its common stock through mid-July 2026, with plans to repurchase at least $5.0 billion for the full year. This commitment to share buybacks is a positive signal for investors, reflecting management's belief in the company's long-term value.

Forward-Looking Catalysts:

Investors should keep an eye on the upcoming quarters for further developments in UnitedHealth Group's operational efficiency and market strategies. Key areas to watch include:

• Continued improvements in the medical care ratio and operating cost management.
• The impact of new initiatives aimed at enhancing affordability and transparency in healthcare.
• Progress in expanding services, particularly in rural healthcare and digital health solutions.

Overall, UnitedHealth Group's Q2 2026 results reflect a strong operational performance and a positive outlook for the remainder of the year, making it an attractive prospect for investors looking for stability and growth in the healthcare sector.

UNITEDHEALTH GROUP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share data; unaudited)

Note: All amounts are in thousands.

Three Months Ended June 30,	2026	2025	Six Months Ended June 30,	2026	2025
Revenues
Premiums	$86,956	$87,905	$174,517	$174,439
Products	13,835	13,564	27,085	26,600
Services	10,018	9,039	19,797	18,011
Investment and other income	1,223	1,108	2,354	2,141
Total revenues	112,032	111,616	223,753	221,191
Operating costs
Medical costs	75,358	78,585	148,847	151,996
Operating costs	14,268	13,778	29,658	27,372
Cost of products sold	13,375	13,019	26,198	25,409
Depreciation and amortization	1,040	1,084	2,069	2,145
Total operating costs	104,041	106,466	206,772	206,922
Earnings from operations	7,991	5,150	16,981	14,269
Interest expense	(962)	(1,027)	(1,917)	(2,025)
Loss on sale of subsidiary and subsidiaries held for sale	(61)	(41)	(133)	(56)
Earnings before income taxes	6,968	4,082	14,931	12,188
Provision for income taxes	(1,298)	(510)	(2,780)	(2,142)
Net earnings	5,670	3,572	12,151	10,046
Earnings attributable to noncontrolling interests	(186)	(166)	(387)	(348)
Net earnings attributable to UnitedHealth Group common shareholders	$5,484	$3,406	$11,764	$9,698
Diluted earnings per share attributable to UnitedHealth Group common shareholders (a)	$6.04	$3.74	$12.94	$10.61
Adjusted earnings per share attributable to UnitedHealth Group common shareholders (b)	$6.38	$4.08	$13.61	$11.29
Diluted weighted-average common shares outstanding	906	910	908	914

UNITEDHEALTH GROUP CONDENSED CONSOLIDATED BALANCE SHEETS (in millions; unaudited)

Note: All amounts are in millions.

	June 30, 2026	December 31, 2025
Assets
Cash and short-term investments	$31,468	$28,121
Accounts receivable, net	21,573	23,018
Other current assets	33,819	39,443
Total current assets	86,860	90,582
Long-term investments	57,716	54,251
Other long-term assets	165,151	164,748
Total assets	$309,727	$309,581
Liabilities, redeemable noncontrolling interests and equity
Medical costs payable	$38,930	$39,337
Short-term borrowings and current maturities of long-term debt	3,827	6,069
Other current liabilities	69,063	69,491
Total current liabilities	111,820	114,897
Long-term debt, less current maturities	69,501	72,320
Other long-term liabilities	22,457	20,666
Redeemable noncontrolling interests	1,436	1,608
Equity	104,513	100,090
Total liabilities, redeemable noncontrolling interests and equity	$309,727	$309,581

Disclaimer

The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information.